"The approach is often to identify what treatments the patients have tried already, so we don't try those again, and then have a discussion about the pros and cons," says J. Quentin Clemens, MD, MSCI.

According to Sanda, future advancements may involve gene and RNA sequencing, the use of AI in imaging, and multidisciplinary collaboration. In this video, Martin G. Sanda, MD, highlights key areas of ...

"There is new technology emerging for skin stimulation of the perineum that is just recently evolving to help control OAB symptoms," says Anne Pelletier Cameron, MD, FRCSC, FPMRS. In this video, Anne ...

The combination of belzutifan and cabozantinib showed promising antitumor activity in treatment-naïve ccRCC patients, with a 70% objective response rate and 98% disease control rate. Median duration ...

Optilume provides durable, long-term relief for urethral strictures, with significant improvements in IPSS, Qmax, and PVR over 5 years. The 5-year freedom from repeat intervention rate was 71.7%, with ...

APPs can significantly alleviate workforce shortages in urology by handling routine clinical tasks, allowing urologists to focus on complex cases. Successful integration of APPs requires changing ...

Urology in the Lab: Researchers link EBV to multiple sclerosis ...

Plasmacytoid urothelial carcinoma is rare and aggressive, with poor outcomes and challenges in accurate staging. National and institutional data reveal discrepancies in chemotherapy use and disease ...

CMS has selected 15 additional drugs for Medicare Part D price negotiations, aiming to lower healthcare costs for enrollees. The Inflation Reduction Act allows Medicare to negotiate drug prices, with ...

"We are trying to develop epigenetic biomarkers that can predict patients that are starting to progress to neuroendocrine prostate cancer," says Jindan Yu, MD, PhD. In this video, Jindan Yu, MD, PhD, ...

Illuccix is approved in Europe for PSMA-positive lesion detection in prostate cancer, following prior approvals in the US, Australia, and Canada. The phase 3 VISION trial showed 177Lu-PSMA-617 plus ...

A panelist discusses how significant unmet needs in NMIBC treatment persist around BCG supply shortages, optimal treatment sequencing, biomarker development for patient selection, and reducing ...